Abstract 2009
Background
The aim of our study was to determine the effect of homologous recombination gene deficiency (HRD) on the effectiveness of platinum chemotherapy and prognosis in patients with pancreatic cancer (PC).
Methods
PubMed and EMBASE database were processed. The search criteria included articles and abstracts till 16.01.2019. Primary outcome was hazard ratio (HR) for overall survival (OS) and 95% confidence interval (CI). Meta-analysis was conducted by «Review Manager» (RevMan) Ver. 5.3.
Results
The request identified 7038 records. A total of 4 studies were included in the meta-analysis and 16 in the systematic review. By the meta-analysis data HRD genotype didn’t affect the prognosis in resectable PC (HR = 1.03, 95% CI 0.46-2.33). By the systemic review average weighted median (AWM) OS for patients with HRD (n = 183) was 34.6 versus 27 months in patients without HRD (n = 1079). For patients who received platinum-based chemotherapy AWM OS was 46.1 months in group with HRD (n = 74) and 36.3 without the HRD (n = 227). For platinum-naive subgroup AWM OS was 24.2 months in HRD (n = 44) and 42.9 in non HRD patients (n = 134). The administration of platinum was associated with more favorable prognosis in HRD patients with resectable PC, but the differences weren`t statistically significant (HR = 0.60, 95% CI 0.36-1.33). For patients with advanced PC AWM OS was 19.8 months in group with HRD (n = 312) versus 15.6 months without HRD (n = 977). In subgroup with platinum, AWM OS was 23.8 and 17.1 months favoring HRD genotype. In subgroup without platinum, AWM OS was 8.3 months vs 12.0 months favoring HRD genotype.
Conclusions
HRD genotype is associated with poor prognosis. But administration of platinum-based chemotherapy can significantly improve the outcome in such a population of pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
This research is conducted under the auspices of the experimental governmental assignment of the Ministry of Health of the Russian Federation and coordinated by the FSBI “Centre for Strategic Planning and Management of Biomedical Health Risks” of the Ministry of Health of the Russian Federation.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5458 - Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen.
Presenter: Philippe Ruszniewski
Session: Poster Display session 2
Resources:
Abstract
1234 - Analysis of PD-1/PD-L1 blockade biomarker and immune infiltrates in Gastroenteropancreatic neuroendocrine carcinoma
Presenter: Jia Zhang Xing
Session: Poster Display session 2
Resources:
Abstract
1517 - Diabetes Is Associated With Pancreatic Neuroendocrine Tumors Growth and Metastasis
Presenter: Zhiyao Fan
Session: Poster Display session 2
Resources:
Abstract
2145 - Investigation of the reclassification of G1/G2 pancreatic neuroendocrine neoplasms by WHO 2017 classification
Presenter: Takahiro Yokose
Session: Poster Display session 2
Resources:
Abstract
3134 - Treatment with somatostatin analogues after radiopeptide therapy
Presenter: Daria Handkiewicz Junak
Session: Poster Display session 2
Resources:
Abstract
2191 - Safety and Tolerability of Surufatinib in Western Patients with Solid Tumors
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3253 - The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours.
Presenter: Rahul Ladwa
Session: Poster Display session 2
Resources:
Abstract
3581 - Opportunist and Serious Infections in Patients with Neuroendocrine Tumors Treated With Everolimus: A Multicenter Study of Real World Patients
Presenter: Carine Mauro
Session: Poster Display session 2
Resources:
Abstract
5374 - Establishment of Prognostic Nomogram Based on the Metastatic Lymph Nodes Ratio for Patients with Gastric Neuroendocrine Tumour
Presenter: yaobin lin
Session: Poster Display session 2
Resources:
Abstract
3951 - Neutrophil-lymphocyte ratio as an independent predictive factor in Neuroendocrine Neoplasms
Presenter: Sofia Ferreira
Session: Poster Display session 2
Resources:
Abstract